Outcome of the Board Meeting held today i.e. November 04, 2026

Evonile Pharma Limited (formerly known as Novartis India Limited) November 04, 2026 The Secretary BSE Limited 1st Floor, New Trading Wing, Rotunda Building Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400 001 Scrip Code: 500672 Sub: Outcome of the meeting of the Board of Directors of Evonile Pharma Limited ( formerly known as Novartis India Limited ) (the “Company”) held today i.e. November 04, 2026 . Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (" SEBI Listing Regulations "), and further to our outcome of the Board Meeting dated October 08, 2026, the Board of Directors of the Company approved and accorded the issuance of partly paid up equity shares of the Company by way of a rights issue (" Rights Issue" and such equity shares, “ Rights Equity Shares ”) to the eligible equity shareholders of the Company for an aggregate amount of up to ₹ 9,000 million (Rupees Nine Thousand Million only) and authoriz ed the ‘Rights Issue Committee’ (“ Committee ”) to decide other terms and conditions of the Rights Issue including the setting of record date, Issue Price, Right entitlement ratio and other related matters in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“ SEBI ICDR Regulations ”). In relation to the aforesaid Rights Issue, the Board of Directors at their meeting held today i.e. November 04, 2026 , approved the payment schedule, utilization of the issue proceeds in relation to the Rights Issue and the Letter of Offer to be filed with BSE Limited and the Securities and Exchange Board of India and the same shall be dispatched to the eligible equity shareholders of the Company . The meeting concluded at 05:20 P.M. IST. The above information shall also be available on the new website of the Company at www.evonilepharma.com . Kindly take the above information on records. For Evonile Pharma Limited (formerly known as Novartis India Limited ) Ms. Chandni Maru Company Secretary and Compliance Officer A60291 Registered Office: Inspire BKC, 7th Floor, Bandra -Kurla Complex, Bandra (East) , Mumbai - 400051, Maharashtra, India . CIN: L24200MH1947PLC006104 | T el: +91 22 50243000 Email: investor.relations@evonilepharma.com | W ebsite: www.evonilepharma.com